These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36573312)

  • 1. Children and caregiver proxy quality of life from peanut oral immunotherapy trials.
    Galvin AD; Vereda A; Rodríguez del Río P; Muraro A; Jones C; Ryan R; Norval D; Jobrack J; Anagnostou A; Wang J
    Clin Transl Allergy; 2022 Dec; 12(12):e12213. PubMed ID: 36573312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials.
    Blumchen K; Kleinheinz A; Klimek L; Beyer K; Anagnostou A; Vogelberg C; Butovas S; Ryan R; Norval D; Zeitler S; Du Toit G
    Allergy Asthma Clin Immunol; 2023 Mar; 19(1):21. PubMed ID: 36915184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials.
    Ciaccio C; Goldsobel AB; Anagnostou A; Beyer K; Casale TB; Deschildre A; Fernández-Rivas M; Hourihane JO; Krawiec M; Lieberman J; Scurlock AM; Vickery BP; Smith A; Tilles SA; Adelman DC; Brown KR;
    Ann Allergy Asthma Immunol; 2022 Dec; 129(6):758-768.e4. PubMed ID: 35973655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy.
    Fernandez-Rivas M; Vereda A; Vickery BP; Sharma V; Nilsson C; Muraro A; Hourihane JO; DunnGalvin A; du Toit G; Blumchen K; Beyer K; Smith A; Ryan R; Adelman DC; Jones SM
    Allergy; 2022 Mar; 77(3):991-1003. PubMed ID: 34320250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peanut (
    Casale TB; Irani AM
    Expert Rev Clin Immunol; 2023 Mar; 19(3):253-265. PubMed ID: 36524617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study.
    Vickery BP; Vereda A; Nilsson C; du Toit G; Shreffler WG; Burks AW; Jones SM; Fernández-Rivas M; Blümchen K; O'B Hourihane J; Beyer K; Anagnostou A; Assa'ad AH; Ben-Shoshan M; Bird JA; Carr TF; Carr WW; Casale TB; Chong HJ; Ciaccio CE; Dorsey MJ; Fineman SM; Fritz SB; Greiner AN; Greos LS; Hampel FC; Ibáñez MD; Jeong DK; Johnston DT; Kachru R; Kim EH; Lanser BJ; Leonard SA; Maier MC; Mansfield LE; Muraro A; Ohayon JA; Oude Elberink JNG; Petroni DH; Pongracic JA; Portnoy JM; Rachid R; Rupp NT; Sanders GM; Sharma HP; Sharma V; Sher ER; Sher L; Sindher SB; Siri D; Spergel JM; Sprikkelman AB; Sussman GL; Tsoumani M; Varshney P; Vitalpur G; Wang J; Yang WH; Zubeldia JM; Smith A; Ryan R; Adelman DC
    J Allergy Clin Immunol Pract; 2021 May; 9(5):1879-1889.e13. PubMed ID: 33359589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy.
    Yu S; Smith A; Hass S; Wu E; Chai X; Zhou J; Ayyagari R; Liu JS; Robison D; Donelson SM; Tilles S
    Adv Ther; 2021 Aug; 38(8):4321-4332. PubMed ID: 34236672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
    O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G
    Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age.
    Du Toit G; Brown KR; Vereda A; Irani AM; Tilles S; Ratnayake A; Jones SM; Vickery BP
    NEJM Evid; 2023 Nov; 2(11):EVIDoa2300145. PubMed ID: 38320526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies.
    DunnGalvin A; Fleischer DM; Campbell DE; O'B Hourihane J; Green TD; Sampson HA; Greenhawt M
    J Allergy Clin Immunol Pract; 2021 Jan; 9(1):216-224.e1. PubMed ID: 32841748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploratory immunogenicity outcomes of peanut oral immunotherapy: Findings from the PALISADE trial.
    Nilsson C; Vereda A; Borres MP; Andersson M; Södergren E; Rudengren M; Smith A; Simon RJ; Ryan R; Fernández-Rivas M; Adelman D; Vickery BP
    Clin Transl Allergy; 2024 Jan; 14(1):e12326. PubMed ID: 38282192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials.
    Brown KR; Baker J; Vereda A; Beyer K; Burks AW; du Toit G; O'B Hourihane J; Jones SM; Norval D; Dana A; Shreffler W; Vickery BP; Casale T; Skeel B; Adelman D
    J Allergy Clin Immunol; 2022 Jun; 149(6):2043-2052.e9. PubMed ID: 34971646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and immunologic outcomes of daily oral immunotherapy for peanut allergy.
    Bird JA; Nilsson C; Brown K; Pham T; Tilles S; du Toit G; Assa'ad A
    J Allergy Clin Immunol Glob; 2023 Aug; 2(3):100120. PubMed ID: 37779517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world experience of pediatric patients treated with peanut (Arachis hypogaea) allergen powder-dnfp.
    Portnoy J; Shroba J; Tilles S; Romdhani H; Donelson SM; Latremouille-Viau D; Bungay R; Chen K; McCann W
    Ann Allergy Asthma Immunol; 2023 May; 130(5):649-656.e4. PubMed ID: 36738781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manufacturing processes of peanut (
    Leonard SA; Ogawa Y; Jedrzejewski PT; Maleki SJ; Chapman MD; Tilles SA; Du Toit G; Mustafa SS; Vickery BP
    Front Allergy; 2022; 3():1004056. PubMed ID: 36304076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The longitudinal impact of probiotic and peanut oral immunotherapy on health-related quality of life.
    Dunn Galvin A; McMahon S; Ponsonby AL; Hsiao KC; Tang MLK;
    Allergy; 2018 Mar; 73(3):560-568. PubMed ID: 29052245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peanut allergy impact on productivity and quality of life (PAPRIQUA): Caregiver-reported psychosocial impact of peanut allergy on children.
    Acaster S; Gallop K; de Vries J; Ryan R; Vereda A; Knibb RC
    Clin Exp Allergy; 2020 Nov; 50(11):1249-1257. PubMed ID: 32866989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peanut (
    Smith SS; Hilas O
    J Pediatr Pharmacol Ther; 2021; 26(7):669-674. PubMed ID: 34588930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Presumed Tree Nut and Peanut Allergy on Quality of Life at Different Ages.
    Pasioti M; Savva M; Lakoumentas J; Kompoti E; Makris M; Xepapadaki P; Papadopoulos NG
    J Clin Med; 2023 May; 12(10):. PubMed ID: 37240577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the Finnish version of the food allergy quality of life questionnaire-parent form (F-FAQLQ-PF).
    Kivistö JE; de Blok BF; Protudjer JLP; Ojaniemi I; Karjalainen J; Huhtala H; Dunn Galvin A
    Acta Paediatr; 2024 Jan; 113(1):91-97. PubMed ID: 37548086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.